Zhitong Finance App News, Da Ren Tang (600329.SH) issued an announcement. Xinxin Pharmaceutical Factory of Jinyao Da Rentang Group Co., Ltd., which belongs to the company, recently received the “Drug Registration Certificate” approved and issued by the State Drug Administration.

Saxagliptin metformin sustained-release tablets (I). This product is suitable for adult patients with type 2 diabetes treated with saxagliptin and metformin to improve blood sugar control in such patients (see instructions for details). This product was developed by Bristol-Myers Squibb in collaboration with AstraZeneca, and has broad market application prospects in long-term blood sugar control and chronic diabetes management in type 2 diabetes. According to the Rice database, sales of saxagliptin metformin extended-release tablets (I) have maintained a significant growth rate in recent years, with total domestic sales of about 480 million yuan in 2025, an increase of about 33% over 2024.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.